Faidra Partheniou joined OGT in June 2015, firstly as Product Manager for the CytoCell® FISH probe range, then leading the Medical Affairs team in which she oversaw the successful FDA de novo clearance of OGT CytoCell AML/MDS probes, the FDA authorisation of the De Novo Classification Request for the CytoCell KMT2A Breakapart FISH Probe Kit PDx as a companion diagnostic (CDx) for Syndax’s first-in-class menin inhibitor, REVUFORJ® (revumenib) and saw OGT become the first FISH probe manufacturer in the world to receive IVDR-certification for a range of FISH probes.
Faidra was appointed Vice President of Regulatory and Medical Affairs in November 2025 with responsibility for delivering OGT’s regulatory processes and clinical developments.
Before joining OGT, Faidra developed extensive experience in clinical cytogenetics working at the Great Ormond Street Hospital and the Royal Free Hampstead NHS Trust both in London, UK.
Visit USA site
Visit Canada site